Mangoceuticals Seeks Patent Expansion for MGX-0024 Antiviral to Cover Animal and Bird Infections
MGRX sits 55% above its 52-week low of $0.335 on light trading volume (0.2× avg).
Summary
Mangoceuticals, Inc. has announced a patent filing to expand the scope of its MGX-0024 antiviral technology. This new filing specifically aims to include the inhibition of respiratory or orally acquired virus infections in animals or birds. This development builds upon the positive data for MGX-0024 that the company reported in an 8-K filing on February 23, 2026. For a company of Mangoceuticals' size, securing and expanding intellectual property protection for its core drug candidates is a material positive event, potentially broadening the addressable market for MGX-0024 beyond human applications. Investors will monitor the progress of this patent application and any subsequent strategic moves to commercialize the technology in the animal health sector.
At the time of this announcement, MGRX was trading at $0.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1M. The 52-week trading range was $0.34 to $5.33. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.